ASCO 2020：11项中华人民共和国研究入选口头报告，17项Poster报告

颇受亚太地区原先冠流感影响，原定于5月初29日~6月初2日在芝加哥举行的美国病理学会（ASCO）年会去年将首次以本站上表达方式举办，这是目前为止最大规模的本站上盛宴。从前，全体会议的简短题目发布，共103个sessions，中会国共有11项科学研究入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

衍生物替尼或拉帕替尼加卡培他滨应用于HER2+帕金森氏症乳腺肿瘤（PHOEBE）：一项III期随机试验中。

第二场：帕金森氏症乳腺肿瘤

写作者：中会国医学科学院的医院徐兵河大学教授、马飞大学教授，复旦大学原为的医院胡夕春大学教授等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可外科手术三阴性乳腺肿瘤国际标准疗程后卡培他滨维持复音化疗的III期试验中（SYSUCC-001）。

第二场：乳腺肿瘤—局部/区域/除此以外疗程

写作者：中会山大学公共卫生中会心王树森大学教授等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

来进行帕金森氏症脑的表型特征来预测脑脊液中会循环DNA侦测的概率: 原先机器结盟据传竞争对手

第二场：原先机器解决据传问题

写作者：刘美芹 刘德兰等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为晚期肝肝细胞肿瘤的一本站疗程：一项停止使用表单、随机、多中会心II/III期试验中。

第二场：小肠肠道肿瘤—小肠腹腔、胰脏和自是

写作者：四川大学棱果的医院毕锋大学教授、中会国人民解放军淮海的医院秦叔逵大学教授等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中会国晚期肝肿瘤病患阿帕替尼二本站疗程：一项随机、安慰剂解读、双盲III期科学研究

第二场：小肠肠道肿瘤—小肠腹腔、胰脏和自是

写作者：中会国人民解放军淮海的医院秦叔逵大学教授、四川大学棱果的医院刘秋大学教授等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

晚期罹患性卵巢肿瘤二次肝细胞减灭术的一项随机III期试验中：SOC1 / SGOG-OV2。

简介：妇科肿瘤症

写作者：复旦大学原为中会山的医院臧荣余大学教授等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治性子宫切除术后除此以外疗程中会的序贯放化疗对比单独超声或启动时放化疗（STARS科学研究）：一项随机、解读、停止使用表单的III期试验中。

全体会议：妇科肿瘤症

写作者：中会山大学公共卫生中会心大白大学教授、刘继红大学教授等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：除此以外吉非替尼对比化疗应用于可切除的EGFR凋亡的N1-N2期NSCLC-随机III期病理试验中的最终总体共存深入研究。

简介：肺肿瘤—非小肝细胞局部-区域/小肝细胞/其他腹部

写作者：广东省人民的医院吴一龙大学教授等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡寡转回非小肝细胞肺肿瘤病患一本站色氨酸转回酶抑制剂联合行动或不联合行动积极前本站局部超声：III期停止使用表单病理随机试验中（SINDAS）的中会期结果（NCT02893332）。

简介：肺肿瘤-非小肝细胞转回

写作者：贵州省人民的医院曾铭大学教授等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对更进一步死亡-1（PD-1）的人源化IgG4单克隆抗体联合行动阿昔替尼应用于帕金森氏症黏膜肺癌病患的Ib期科学研究的总共存期和人类；也深入研究。

简介：肺癌/皮肤肿瘤

写作者：南京大学的医院郭军、盛锡楠大学教授等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全性和结果：通用CAR-T肝细胞首次体内试验中疗程罹患/难治性T肝细胞急性淋巴肝细胞肺炎（r/r T-ALL）的安全性和。全体会议：合作开发中会的疗程技术-免疫疗程。写作者：王好在等简短：3013的广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在晚期腹腔鳞状肝细胞肿瘤病患中会的应用：一项随机的停止使用表单II期试验中（ORIENT-2）。全体会议：小肠肠道肿瘤-小肠腹腔肿瘤、胰脏肿瘤和自是道肿瘤写作者：徐建明大学教授等简短：4511的广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T肝细胞对炎母肝细胞瘤的根除性疗程全体会议：中会枢神经系统写作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东简短：2522的广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在晚期错配修复缺陷病患中会的应用全体会议：合作开发中会的疗程学-免疫疗程写作者：沈琳大学教授等简短：3021的广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 增生CD7-CART疗程罹患/难治性ACUTE淋巴肝细胞肺炎/淋巴瘤的唯一未体内病理试验中全体会议: 合作开发性疗程学-免疫疗程写作者简介：张明志，南部县等简短：3026的广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合行动应应用于晚期也就是说瘤病患的Ib期科学研究全体会议：发展性疗程学--分子结构靶向药物和人类学写作者：龚继芳，沈琳大学教授等简短：3523的广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动类固醇和nedaplatin疗程罹患性或帕金森氏症腹腔鳞状肝细胞肿瘤（ESCC）病患的II期科学研究。全体会议：小肠肠道肿瘤-小肠腹腔、胰脏和自是道肿瘤的科学研究写作者：王志强劲，刘玉红，王德申，王凤华，任超，谭琼 王志强劲、刘玉红、王德深、王凤华、任超、谭琼简短：4522的广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体会议：小肠肠道肿瘤-小肠腹腔肿瘤、胰脏肿瘤和自是管肿瘤的二本站疗程写作者：宋艳等简短：4524的广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体马蹄形RNA分类器应用于初始活检时侦测高等级肿瘤的唾液外体马蹄形RNA分类器：一项多中会心的回顾性科学研究全体会议：泌尿泌尿系统肿瘤症---肿瘤、睾丸肿瘤和肿瘤写作者简介：Liaoyuan Li等简短：5522的广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 局部晚期宫颈肿瘤模版化疗后的除此以外化疗全体会议: 妇科肿瘤症写作者简介： 刘珉珉等简短：6031的广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺炎性肿瘤的表征：基于ALTER01031试验中的深入研究。会讲：外周写作者：哈尔滨市的医院娴熟大学教授简短：6526的广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、微小和平均年龄对安洛替尼疗程后病患结局的影响: ALTER01031的亚组深入研究全体会议：外周写作者：哈尔滨市的医院娴熟大学教授简短：6527的广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究预测I-IIIA期非小肝细胞肺肿瘤（NSCLC）病患术后罹患: GASTO1035和GASTO1018的结果全体会议：肺肿瘤-非小肝细胞局部-区域性/小肝细胞/小肝细胞/其他胸科肿瘤症写作者：Si-Yu Wang等简短：9023的广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小肝细胞肺肿瘤（NSCLC）中会EGFR色氨酸转回酶抑制剂的原先型耐药机制全体会议:肺肿瘤-非小肝细胞帕金森氏症肺肿瘤写作者简介：赵昕，金恰巧，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金恰巧、满宇、欧秋香、华宝、薛武、杨绍、范敏简短：9528的广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验中中会晚期肺癌总共存的替代终点全体会议：肺癌/皮肤肿瘤写作者：聂润聪，袁书强劲，刘元芳，陈英波，周志伟 聂润聪、袁书强劲、刘元芳、陈英波、周志伟简短：10030的广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程罹患或帕金森氏症原发性恶性肩胛骨病患的II期科学研究全体会议： 甲状腺肿写作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简短：11525的广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在晚期甲状腺肿病患多本站疗程中会的安全性和。全体会议：甲状腺肿写作者：姚伟涛，王家强劲，张鹏，王欣，杜原先辉，田志浩，牛晓颖 姚伟涛、王家强劲、张鹏、王鑫、杜鑫辉、田志超、牛晓英简短：11526的广告：414